Linsitinib - CAS 867160-71-2
Catalog number: 867160-71-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Linsitinib, also known as OSI-906, is  an orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity.  OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Overexpressed in a variety of human cancers, IGFR-1 stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis.
white solid powder
OSI-906; OSI906; OSI 906.
Canonical SMILES:
Current Developer:
OSI Pharmaceuticals, Inc.
1.Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
Macaulay VM1, Middleton MR2, Eckhardt SG3, Rudin CM4, Juergens RA5, Gedrich R6, Gogov S7, McCarthy S8, Poondru S9, Stephens AW10, Gadgeel SM11. Clin Cancer Res. 2016 Feb 1. [Epub ahead of print]
PURPOSE: Cross-talk between type I IGF receptor (IGF1R), insulin receptor (INSR), and epidermal growth factor receptor (EGFR) mediates resistance to individual receptor blockade. This study aimed to determine the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of linsitinib, a potent oral IGF1R/INSR inhibitor, with EGFR inhibitor erlotinib.
2.Mass balance, pharmacokinetics, and metabolism of linsitinib in cancer patients.
Poondru S1, Chaves J2, Yuen G3, Parker B4, Conklin E5, Singh M3, Nagata M5, Gill S3. Cancer Chemother Pharmacol. 2016 Apr;77(4):829-37. doi: 10.1007/s00280-016-2999-5. Epub 2016 Mar 14.
PURPOSE: This study characterized the pharmacokinetics, mass balance, routes and extent of elimination, metabolites, and safety of a single oral dose of (14)C-linsitinib, an IGF-1R/IR inhibitor, in patients with advanced solid tumors. The tolerability of linsitinib after multiple-dose administration was assessed in those patients who wished to continue treatment beyond the single (14)C-linsitinib dose.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related IGF-1R Products

CAS 475488-23-4 ADW742

(CAS: 475488-23-4)

NVP-ADW742 is a novel small weight molecular inhibitor of IGF-IR with potential anticancer activity. NVP-ADW742 inhibited IGF-IR-mediated proliferation with an...

CAS 477-47-4 Picropodophyllin

(CAS: 477-47-4)

Picropodophyllin, also known as Picropodophyllotoxin, AXL1717 or PPP, is a cyclolignan alkaloid found in the mayapple plant family (Podophyllum peltatum), and a...

CAS 1089283-49-7 GSK-1904529a

(CAS: 1089283-49-7)

GSK-1904529A is an IGF-1R Inhibitor, is is a promising candidate for therapeutic use in IGF-IR–dependent tumors. GSK1904529A selectively inhibits IGF-IR and I...

CAS 196868-63-0 PQ 401

PQ 401
(CAS: 196868-63-0)

PQ 401 is an IGF-1R inhibitor and inhibits autophosphorylation of the IGF-IR kinase domain at concentrations <100 nM, with an IC50 <1μM.

CAS 557795-19-4 Sunitinib

(CAS: 557795-19-4)

Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.

CAS 475489-16-8 AEW-541

(CAS: 475489-16-8)

AEW541, also known as NVP-AEW541, is a novel, potent IGF-IR kinase inhibitor. NVP-AEW541 is capable of distinguishing between the IGF-IR (IC50 = 0.086 microM...

CAS 1001350-96-4 BMS-754807

(CAS: 1001350-96-4)

BMS-754807 is an orally bioavailable antagonist of human insulin-like growth factor type I receptor (IGF-1R) with potential antineoplastic activity. BMS-7548077...

CAS 1054315-48-8 BMS695735

(CAS: 1054315-48-8)

BMS695735 is a benzimidazole inhibitor of the insulin-like growth factor-1 receptor. It was also found to have potent CYP3A4 inhibition. It has broad spectrum i...

Chemical Structure

CAS 867160-71-2 Linsitinib

Quick Inquiry

Verification code

Featured Items